Strategic Partnerships Molecular Partners has active and expanding partnerships across radiopharmaceuticals, including collaboration with Orano Med and PanTera, plus a non-exclusive development agreement with Eckert & Ziegler. This presents a ready-made entry point for co-development, licensing conversations, and joint venture opportunities in Radio-DARPin programs.

Radio-DARPin Focus The company is advancing Radio-DARPins and targeted alpha therapies with broad oncology potential, including a lead candidate MP0712 in multicenter trials. This positioning creates sales opportunities with radiopharma manufacturers, imaging centers, and contract manufacturing organizations seeking novel radioligand therapy platforms.

Clinical Progress With programs in pre-clinical to clinical stages and a lead asset in Phase 1/2a, there is a window for early-stage collaborators and CROs to provide clinical development, regulatory strategy, and translational research support, as well as opportunities for investors evaluating pipeline risk-adjusted returns.

Global Footprint Having offices in Zürich and Concord, MA, along with participation in major conferences (ASCO, SNMMI, Gordon Research Conference) indicates access to North American and European markets, enabling regional partnerships, market access discussions, and cross-border manufacturing or distribution arrangements.

Technology Enablement Leveraging a tech stack that includes cloud platforms (Google Cloud), data analytics (Databricks, Apache Spark), and digital collaboration tools suggests opportunities to offer data-driven collaboration, real-world evidence collection, and optimized clinical trial operations through integrated tech solutions.